CLLS Cellectis SA ADRs

Cellectis SA is a gene-editing company, employing its core proprietary technologies to develop products in the emerging field of immuno-oncology. Its two segment includes Therapeutics and Plants. This is an ADR of a company whose stock trades outside of the U.S. as the symbol FP:ALCLS.

$2.92  -0.29 (-9.03%)
As of 06/28/2022 15:59:58 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  France
Country of incorporation:  France
IPO date:  03/25/2015
Outstanding shares:  45,510,810
Average volume:  151,992
Market cap:   $141,993,727
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BWFKZT2
Valuation   (See tab for details)
PE ratio:   -1.06
PB ratio:   0.74
PS ratio:   4.25
Return on equity:   -70.27%
Net income %:   -402.03%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy